

Design, Synthesis, and Structure–Activity Relationships of Pyridoquinazolinecarboxamides as RNA Polymerase I Inhibitors

Laureen Colis,^{†,‡} Glen Ernst,[‡] Sara Sanders,[§] Hester Liu,[†] Paul Sirajuddin,[†] Karita Peltonen,^{||} Michael DePasquale,[‡] James C. Barrow,^{‡,§} and Marikki Laiho^{*,†,||,⊥}

[†]Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, Maryland 21287, United States


[‡]Lieber Institute for Brain Development, 855 North Wolfe Street, Baltimore, Maryland 21205, United States

[§]Department of Pharmacology, Johns Hopkins University School of Medicine, 855 North Wolfe Street, Baltimore, Maryland 21287, United States

^{||}Center for Drug Research, University of Helsinki, Viikinkaari 9, 00014 Helsinki, Finland

[⊥]Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1550 Orleans Street, Baltimore, Maryland 21287, United States

ABSTRACT: RNA polymerase I (Pol I) is a dedicated polymerase that transcribes the 45S ribosomal (r) RNA precursor. The 45S rRNA precursor is subsequently processed into the mature 5.8S, 18S, and 28S rRNAs and assembled into ribosomes in the nucleolus. Pol I activity is commonly deregulated in human cancers. On the basis of the discovery of lead molecule BMH-21, a series of pyridoquinazolinecarboxamides have been evaluated as inhibitors of Pol I and activators of the destruction of RPA194, the Pol I large catalytic subunit protein. Structure–activity relationships in assays of nucleolar stress and cell viability demonstrate key pharmacophores and their physicochemical properties required for potent activation of Pol I stress and cytotoxicity. This work identifies a set of bioactive compounds that potently cause RPA194 degradation that function in a tightly constrained chemical space. This work has yielded novel derivatives that contribute to the development of Pol I inhibitory cancer therapeutic strategies.



INTRODUCTION

Ribosomal (r) DNA is the most highly transcribed genomic region and occurs in a dedicated subcellular compartment, the nucleolus.^{1,2} Transcription of rRNA is mediated by RNA polymerase I (Pol I) that transcribes the multicopy rDNA gene to a long 45S rRNA precursor.³ The 45S rRNA precursor is processed through multiple steps to the 18S, 5.8S, and 28S mature rRNAs requisite for the assembly of the ribosomes. Pol I transcription is initiated by binding of a multisubunit preinitiation complex to rDNA promoter, which stochastically recruits the Pol I holo complex.⁴ The Pol I holo complex is composed of 14 subunits in eukaryotes, of which the subunits RPA194, RPA135, and RPA12 form the catalytically active site. Destabilization of the rDNA helix, or loss of the protein framework, will effectively stall transcription.⁵

The rate of rRNA transcription is tightly controlled by external signaling pathways that cause the assembly and binding of the preinitiation complex. Deregulation of rRNA synthesis is highly frequent in human cancers.^{6–8} This is due to activation of extracellular and intracellular signaling pathways and oncogenes such as Myc, Neu, Akt/PKB, and mTOR that

promote the preinitiation complex assembly and hence increase the rate of rRNA transcription. Conversely, loss-of-function of tumor suppressors p53, pRB, ARF, and PTEN leads to activation of Pol I transcription.⁷ Cancer cells have a high degree of dependency on protein synthesis in general due to their increased needs for proteins requisite for their high proliferation rates and to compensate for their proteotoxic environment, misfolding, and errors in protein synthesis.⁹ These presumably create a setting in which cancer cells acquire dependency on increased rRNA synthetic rates, which are supported by the convergence of cancer cell deregulated pathways. Therefore, inhibitors of Pol I transcription may provide novel approaches toward cancer therapies.

Despite the key impact of Pol I contributing to cancer cell characteristics, its therapeutic exploitation has been minimal. Compound 1 (CX-5461) is a recently described small molecule that inhibits Pol I preinitiation complex (Figure 1).^{10–12} We have recently presented the discovery of an anticancer small

Received: March 27, 2014

Published: May 21, 2014




Figure 1. RNA Pol inhibitors 1 and 2 and the inactive analogue 3.

Scheme 1. General Scheme for the Synthesis To Provide Generic Structure 7





Figure 2. Effect of compounds on expression and localization of RPA194 and NCL. Immunofluorescence staining of U2OS cells treated with the indicated compounds ($0.5 \mu\text{M}$) for 3 h. Cells were stained for (A) RPA194 (red) and (B) NCL (green) and counterstained for DNA (blue). Scale bars, $10 \mu\text{m}$.

molecule, 12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide, *N*-[2(dimethylamino)ethyl]-12-oxo (compound 2, BMH-21) (Figure 1).¹³ It has a distinct mode of inhibition of Pol I compared to compound 1, an inhibitor of Pol I preinitiation complex assembly.¹⁰ Our studies demonstrated that compound 2 intercalates with GC-rich rDNA, inhibits Pol I, and causes proteasome-mediated degradation of RPA194.¹⁴ Compound 2 also showed broad and potent anticancer activity in NCI60 cancer cell lines and reduced tumor burden in mouse xenograft assays. These studies have provided proof-of-principle confirmation that Pol I targeting is a feasible approach for cancer control.^{12,14}

Compound 2 was identified by screening commercially available libraries, with few readily available analogues. The goal of this study was to assess its structure–activity relationships (SARs) with respect to Pol I transcription stress and RPA194 degradation and their association with cytotoxicity.

RESULTS

Chemistry. Synthesis of Pyridoquinazolinecarboxamide Derivatives. Compound 2 inhibits Pol I transcription and causes nucleolar stress as measured by nucleolar protein relocation and expression at submicromolar concentrations.¹⁴ A structurally similar small molecule, BMH-21a1 (3) (Figure 1), that lacks an amino group in the *N,N*-




Figure 3. Quantitative image analysis of expression and localization of RPA194 and NCL by the derivatives. U2OS cells were treated with the compounds at 0, 0.1, 0.5, 1, and 5 μM and incubated for 3 h. Cells were fixed and stained for (A) RPA194 and (B) NCL and counterstained for DNA and imaged using epifluorescence. Quantitative image analysis for RPA194 degradation (A) and loss of NCL nucleolar intensity was conducted based on two biological replicates, and the fold change to control is shown. Error bars represent SEM.

dimethylamino carboxamide arm was devoid of all activities.¹⁴ This was indicative that the *N,N*-dimethylamino carboxamide arm was relevant for the biological activity of compound 2. To test this hypothesis and to explore other active moieties, we conducted SAR analysis. For this purpose, synthesis of the desired compounds was achieved as shown in Scheme 1, where the acid 6, synthesized from compounds 4 and 5, was coupled to a variety of amines to give the desired products with generic structure 7 (Scheme 1) and as detailed in the Experimental Section.

Evaluation of RPA194 Degradation and Nucleolar Stress in U2OS Cancer Cell Line. We have shown that the Pol I inhibitory activity of compound 2 is reflected as nucleolar stress, that is, translocation of nucleolar marker proteins, such as nucleolin (NCL) to the nucleoplasm, and degradation of RPA194, the large catalytic subunit of Pol I.¹⁴ We hence used these as readouts to assess the biological activity of the derivatives. For this purpose U2OS osteosarcoma cells were seeded on glass coverslips incubated with 2 log titration of the compounds for 3 h, fixed, and immunostained for RPA194 and NCL. As shown in representative images in Figure 2A, RPA194 expression was affected to a variable degree by the compounds. At 0.5 μM concentration shown, compounds 8, 9, 10, 11, 12, and 13 led to an almost complete loss of expression of RPA194,

similar to compound 2, while compounds 14, 15, and 36 had no effect. Similarly, derivatives 8, 9, 10, 11, 12, and 13 decreased the nucleolar localization of NCL and led to its translocation to the nucleoplasm (Figure 2B). Quantitative image analysis was conducted for expression of RPA194 and NCL over the full concentration range, and IC_{50} was determined (Figure 3 and Tables 1–4). Compound 2 IC_{50} values for degradation of RPA194 and translocation of NCL were very similar ($0.05 \pm 0.04 \mu\text{M}$ and $0.07 \pm 0.06 \mu\text{M}$, respectively) and showed its submicromolar activity. Quantitative image analysis for these RPA194 and NCL phenotypes was then employed to assess the bioactivity of the compounds.

SAR Analysis. As shown in Table 1, significant changes to the structure of compound 2 were poorly tolerated. As expected, truncation of the intercalator portion of the molecules (compounds 15 and 16) reduced the activity by over 40-fold by reducing π -stacking contacts with the DNA bases. Therefore, attention was focused on the amide side chain. Conversion of the amide to an ester resulted in a significant loss in potency of compound 17 as did alkylation of the amide NH (compounds 18 and 19), which rendered the molecule either inactive or caused >400-fold decrease in potency. Replacement of the pendent basic amine with less basic heterocycles such as imidazole (compound 20) and

Table 1. Compound 2 Core Modifications


Structure	Compound	cLogD ^a	pKa ^b	RPA194 IC ₅₀ ^c	NCL IC ₅₀ ^d
	2	1.59	8.6	0.05 ± 0.04	0.07 ± 0.06
	15	0.25	8.6	2.17 ± 0.24	3.17 ± 0.67
	16	-0.15	9.2	1.35 ± 0.15	3.28 ± 0.42
	17	1.97	8.2	50.90*	12.30*
	18	1.0	8.6	22.10*	>100*
	19	1.46	8.6	>100*	>100*
	20	1.67	7.1	0.98 ± 0.86	26.05 ± 8.65
	21	2.55	5.3	11.80*	>100*
	22	2.55	5.7	15.84 ± 6.16	>100
	23	1.50	--	13.10*	1.97*
	24	3.70	--	31.70 ± 8.30	>100
	25	0.95	--	5.21 ± 1.70	>100

^acLogD calculated at pH 7.4 by ACD Labs Percepta. ^bpK_a calculated by ACD Labs Percepta. ^cRPA IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments except when noted with *. ^dNCL IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments except when noted with *.

pyridine (compounds 21 and 22) was also not tolerated. Other heterocycles and nonbasic functional groups (compounds 23,

24, 25) were also not tolerated. All these led to >200-fold decrease in potency or rendered the molecule inactive.


Table 2. Compound 2 Other Linkers



Structure	Compound	cLogD ^a	pKa ^b	RPA194 IC ₅₀ ^c	NCL IC ₅₀ ^d
	14	0.34	10.0	0.66 ± 0.08	1.53 ± 0.53
	26	0.44	9.2	0.43 ± 0.27	0.48 ± 0.26
	27	-0.1	9.7	2.01 ± 0.92	2.63 ± 0.08
	28	0.45	9.2	33.85 ± 16.65	>100

^acLogD calculated at pH 7.4 by ACD Labs Percepta. ^bpK_a calculated by ACD Labs Percepta. ^cRPA IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments. ^dNCL IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments.

Table 3. Compound 2 Linker Constraints




Structure	Compound	cLogD ^a	pKa ^b	RPA194 IC ₅₀ ^c	NCL IC ₅₀ ^d
	12	0.01	9.7	0.21 ± 0.11	0.18 ± 0.08
	29	1.08	9.4	0.18 ± 0.08	1.38 ± 0.88
	30	2.73	--	35.40*	>100*
	31	2.19	7.2	>100	>100
	32	0.41	9.1	41.99 ± 35.82	>100
	33	0.68	8.6	>100	>100
	34	0.65	9.2	31.80*	10.60*

^acLogD calculated at pH 7.4 by ACD Labs Percepta. ^bpK_a calculated by ACD Labs Percepta. ^cRPA IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments except when noted with *. ^dNCL IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments except when noted with *.

The SAR based on the early analogue, compound 3, suggested that a basic amine was critical and that only

conservative changes to compound 2 were to be tolerated. Compounds 14, 26, 27, and 28 in Table 2 show the effect of

Table 4. Compound 2 Two-Carbon Linker Variations



Structure	Cmpd	cLogD ^a	pKa ^b	RPA194 IC ₅₀ ^c	NCL IC ₅₀ ^d	Microsome T _{1/2} ^e
	2	1.59	8.6	0.05 ± 0.04	0.07 ± 0.06	57
	8	1.53	8.8	0.18 ± 0.04	0.08 ± 0.03	25
	9	0.59	9.1	0.09 ± 0.06	0.08 ± 0.07	33
	10	1.00	9.2	0.14 ± 0.01	0.19 ± 0.01	21
	11	1.43	8.6	0.11 ± 0.02	0.16 ± 0.02	54
	13	1.35	8.6	0.04 ± 0.02	0.04 ± 0.03	43
	35	1.1	9.4	3.04 ± 0.19	1.70 ± 0.86	NT
	36	1.62	5.9	1.25 ± 1.00	0.60 ± 0.13	NT
	37	1.06	8.0	1.09 ± 0.24	1.84 ± 0.43	43
	38	1.33	7.1	0.73*	0.70*	14

^acLogD calculated at pH 7.4 by ACD Labs Percepta. ^bpK_a calculated by ACD Labs Percepta. ^cRPA IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments except when noted with *. ^dNCL IC₅₀ represents mean ± SEM (μM); assays represent duplicate independent biological experiments except when noted with *. ^eHuman liver microsome T_{1/2} in minutes.

changing the distance of the basic amine from the tetracycline (IC₅₀ of 0.66, 0.43, 2.01, and 33.85 μM for the RPA194 assay, respectively), and once again, the two-carbon linker present in compound **2** appeared optimal.

Several cyclic constraints to the two-carbon linker were explored as shown in Table 3, and compounds **12** and **29** retained most of the activity (IC₅₀ of 0.21 and 0.18 μM, respectively), but no constraint was found that improved potency. Compounds **30**, **31**, **32**, **33**, **34** were inactive. More subtle changes to the two-carbon linker were explored as shown in Table 4. Wrapping the terminal methyl groups of compound **2** into rings or to larger ethyl group provided compounds with similar potency (compounds **8**, **9**, and **10** IC₅₀ of 0.18, 0.09, and

0.14 μM, respectively), compared to isopropyl (compound **35** IC₅₀ of 3.04 μM) alkyl chains, which was poorly tolerated. Conversion of the piperidine in compound **8** to a morpholine (compound **36** IC₅₀ of 1.25 μM) or piperazine (compound **37** IC₅₀ of 1.09 μM) reduced potency, as did appending a methoxyethyl (compound **38** IC₅₀ of 0.73 μM). Addition of methyl groups into the linker (compounds **11** and **13**, IC₅₀ of 0.11 and 0.04 μM) was tolerated with compound **13** representing the most potent variant prepared. In general, there was good agreement between the RPA194 and NCL assays, with the NCL assay showing slightly more sensitivity toward changes in the structure.

The changes in RPA194 expression observed by immunofluorescence were confirmed for representative derivatives by Western blotting analysis of cell lysates (Figure 4). Similar to




Figure 4. Protein expression analyses for RPA194 and NCL. U2OS cells were treated with the compounds at 0, 0.1, 1, and 10 μM and incubated for 3 h. Protein was extracted using RIPA lysis buffer, and Western blotting was conducted for RPA194, NCL, and GAPDH as control.

compound 2, compounds 8 and 11 caused degradation of RPA194, whereas other tested compounds were less potent in doing so (compounds 14, 15, 36) or were inactive (compound 18). The translocation of NCL to the nucleoplasm by compound 2 does not affect the expression of the protein.¹⁴ Accordingly, the expression of NCL was largely unaffected except at very high (10 μM) concentrations of compound 2 and other active derivatives (Figure 4).

Derivatives That Cause Nucleolar Stress Decrease U2OS Cancer Cell Viability. Selected derivatives were then tested for their effect on viability of U2OS cells. Cells were cultured for 48 h in the presence of the compounds, and viability was determined using WST1 assay. As shown in Figure 5, derivatives that elicited potent degradation of RPA194 (8, 9, 13) caused profound loss of cell viability similar to compound 2, whereas compounds 14, 15, 18, and 36 had little or no activity. This suggested that loss of viability was coupled with

loss of RPA194 and nucleolar stress as demonstrated for compound 2.¹⁴

Physicochemical Characterization. The derivatives were analyzed with respect to their physicochemical properties using ACD Labs Percepta prediction software. The pK_a of the derivatives varied between 5.3 and 9.96. All active derivatives were highly basic and had pK_a values between 8.6 and 9.7 and were closely comparable to that of the parent compound with predicted pK_a at 8.6 (Tables 1–4). cLogD estimates at pH 7.4 showed variation between -0.15 and 3.7 where the active derivatives possessed values between 0.59 and 1.59 (Tables 1–4). Finally, given that the previously described inactive analogue, compound 3, was distinguished by lack of the terminal amine and the prediction that this nitrogen is protonated (ref 14), we assessed the predicted protonation of the derivatives at pH 7.4. All derivatives with predicted lack or low degree of protonation, based on pK_a values and predictions using ChemAxon Marvin analysis program (not shown), were biologically inactive (Tables 1–4). We conclude that the main physicochemical determinants for biologically active derivatives included the protonation of the terminal amine and a closely defined basic pK_a resembling that of the parent.

Metabolism Studies. Compound 2 has a remarkably good PK profile with good exposure and a half-life of 2.5 h after 25 mg/kg ip dose.¹⁴ By use of an in vitro human liver microsomal stability assay, compound 2 had an in vitro half-life of 57 min. Several of the active analogues prepared were tested in this paradigm (Table 4), and despite modification of the terminal methyl metabolic soft spots, none of the analogues tested significantly improved the in vitro stability. While identification of the major metabolites of compound 2 showed N-dealkylation as one of several major metabolites, modifications that would be predicted to slow dealkylation (compounds 8, 9, and 10) did not improve stability, despite a range of calculated cLogD values (Table 4).

DISCUSSION AND CONCLUSION

A series of compound 2 variants were prepared and evaluated as potential novel anticancer agents that act via the repression of Pol I activity. The activity of compound 2 is due to its ability to intercalate to GC-rich rDNA sequences,¹⁴ which makes it very different from other four-ring anthracyclines that tend to cause DNA damage.¹⁵ Their intercalation modalities are also quite distinct from the anthracyclines intercalating perpendicular to the DNA helix, whereas compound 2 intercalates in a near-parallel fashion.¹⁴ While our previous modeling has




Figure 5. Cell viability assay. U2OS cells were treated with the compounds at 0, 0.5, and 5 μM and incubated for 48 h. Cell viability was determined using WST-1 assay. $N = 2$ biological repeats. Error bars represent SEM.

suggested some molecular determinants for this activity, the high sensitivity of the pendent compound **2** chain as exemplified in Table 4 suggests that there may be other components to the 2–DNA complex that lead to its biological activity. Notably, all near equipotent derivatives retained a predicted protonation of the terminal amine and had a basic pK_a close to that of the parent at 8.6. These findings indicated that the overall charge of the molecule was critical as well as maintaining the length and basic charge close to the end of the carboxamide arm. Considering molecular modeling of compound **2** in ref 14, these findings suggest that compound **2** intercalates with acidic DNA complemented with additional electrostatic interactions. It also raises the possibility that derivatives with more highly charged moieties may change the nature of the intercalation or that those with larger molecular sizes alter the DNA intercalation cavity. This further implies that such molecules could perturb other DNA metabolic processes.

The key marks used here to define compound **2** activity were based on biological assays measuring the integrity of the nucleolus, expression and localization of nucleolar proteins, and cell viability. Nucleolar stress, characterized by nucleolar protein relocalization, such as NCL and loss of integrity of the nucleolus is a hallmark of Pol I transcription stress and its inhibition⁵ and is rapidly and profoundly activated by compound **2**. Degradation of RPA194, the large catalytic subunit of Pol I, is a distinctive and unique response to compound **2**.¹⁴ Hence, these markers function as definitive and sensitive cellular indicators for compound **2** activity. As shown here, the parent molecule activated RPA194 degradation and NCL translocation at IC_{50} of 50–70 nM. Assays for degradation of RPA194 and NCL translocation by the derivatives were highly consistent with each other, indicating their usefulness in further cell-based screens for Pol I transcription inhibitors.

As determination of the derivative activities were based on cellular assays, the changes in potency could reflect their permeability. Large changes in potency of the derivatives were observed across a wide range of physicochemical properties, as illustrated by their cLogD values shown in the Tables 1–4. The compound cLogD ranged between –0.15 and 3.7, and very potent compounds existed at either end (compound **12** cLogD of 0.01, compound **8** cLogD of 1.53), suggesting that permeability alone did not determine the phenotypes.

The structure–activity relationships described herein have defined key structural elements in the compound **2** structure such as the four-ring tetracycle, secondary amide bond and two-carbon link to a basic amine, and charge. Variations around this theme have led to very potent novel analogues such as compounds **8**, **9**, **12** and **13**, which retain the desirable potency and DMPK properties compared to compound **2**. These compounds share close potency for both RPA194 degradation and NCL localization change as reflection of Pol I transcription stress. Given that Pol I transcription is an emerging therapeutic target, development of such bioactive compounds holds substantial promise.

EXPERIMENTAL SECTION

Synthesis. General Methods. All commercially available reagents and solvents were used without further purification unless otherwise stated. Automated flash chromatography was performed on an ISCO CombiFlash Rf or Biotage Isolera using Biotage Flash cartridges with peak detection at 254 nm. Reverse phase purification was

accomplished using a Gilson 215 liquid handler equipped with a Phenomenex C18 column (150 mm × 20 mm i.d., 5 μ m). Peak collection was triggered by UV detection at 214 or 254 nm. ¹H NMR spectra were recorded on a Bruker 400 instrument operating at 400 MHz with tetramethylsilane or residual protonated solvent used as a reference. Analytical LC/MS was performed using Agilent 1260 equipped with autosampler (Agilent Poroshell 120 C18 column (50 mm × 4.6 mm i.d., 3.5 μ m); 0.1% TFA in water/acetonitrile gradient; UV detection at 215 and 254 nm) and electrospray ionization. All final compounds showed purity greater than 95% at 215 and 254 nm using this method.

12-Oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxylic Acid (6a). A mixture of 3-amino-2-naphthoic acid (**5**) (2.00 g, 10.68 mmol), 2-chloronicotinic acid (**4**) (1.68 g, 10.68 mmol), and hydrochloric acid (0.9 mL, 29.13 mmol) in ethanol (70 mL) was stirred at 80 °C for 66 h (for convenience). After cooling, the reddish-orange suspension was filtered, washed with ethanol, and air-dried to give 12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxylic acid (1.56 g, 5.37 mmol, 50.3% yield) as a yellow-orange solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 9.16 (s, 1 H), 9.03 (dd, *J* = 7.20, 1.64 Hz, 1 H), 8.63 (dd, *J* = 6.95, 1.64 Hz, 1 H), 8.49 (s, 1 H), 8.34 (d, *J* = 8.34 Hz, 1 H), 8.19 (d, *J* = 8.08 Hz, 1 H), 7.76 (t, *J* = 7.07 Hz, 1 H), 7.64 (t, *J* = 6.95 Hz, 1 H), 7.18 (t, *J* = 7.07 Hz, 1 H). MS [*M* + 1] = 291.

11-Oxopyrido[2,1-b]quinazoline-6-carboxylic Acid (6b). A mixture of 2-aminobenzoic acid (250 mg, 1.82 mmol), 2-chloronicotinic acid (287.2 mg, 1.82 mmol), and hydrochloric acid (0.3 mL, 9.85 mmol) in ethanol (20 mL) was stirred at 80 °C for 48 h (for convenience). After cooling, the reddish-orange suspension was filtered, washed with ethanol, and air-dried to give 11-oxopyrido[2,1-b]quinazoline-6-carboxylic acid (107 mg, 0.45 mmol, 24.5% yield) as a pale yellow solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 9.50 (dd, *J* = 7.07, 1.52 Hz, 3 H), 9.18 (dd, *J* = 7.45, 1.64 Hz, 3 H), 8.56 (dd, *J* = 8.21, 1.39 Hz, 3 H), 8.17 (ddd, *J* = 8.46, 7.20, 1.52 Hz, 3 H), 8.03 (s, 2 H), 8.01 (s, 1 H), 7.80 (ddd, *J* = 8.15, 7.26, 1.01 Hz, 4 H), 7.72 (t, *J* = 7.20 Hz, 3 H). MS [*M* + 1] = 241.

Method A: Synthesis of Amide Analogues (7). *N*-[2-(Dimethylamino)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (**2**). To a solution of 12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxylic acid (50 mg, 0.17 mmol) and TBTU (82.9 mg, 0.26 mmol) in DMF (1 mL) was added DIPEA (90 μ L, 0.52 mmol). After the contents were stirred at room temperature for 15 min, *N,N*-dimethylethylenediamine (28.4 μ L, 0.26 mmol) was added and stirring continued for 16 h (for convenience). The reaction mixture was added to 100 mL of cold water with stirring. The solid was collected by filtration and dried under vacuum to give *N*-[2-(dimethylamino)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (36 mg, 0.10 mmol, 58.0 % yield) as a yellow solid. ¹H NMR (400 MHz, DMSO-*d*₆) δ ppm 11.50 (br s, 1 H), 9.10 (s, 1 H), 8.91 (d, *J* = 5.81 Hz, 1 H), 8.55 (d, *J* = 5.56 Hz, 1 H), 8.28–8.34 (m, 2 H), 8.12 (d, *J* = 8.34 Hz, 1 H), 7.73 (t, *J* = 7.45 Hz, 1 H), 7.61 (t, *J* = 7.33 Hz, 1 H), 7.05 (t, *J* = 7.07 Hz, 1 H), 3.56 (d, *J* = 5.05 Hz, 2 H), 2.59 (t, *J* = 5.94 Hz, 2 H), 2.40 (s, 6 H). ¹H NMR (400 MHz, CDCl₃) δ ppm 11.70 (br s, 1 H), 9.10 (s, 1 H), 8.94 (dd, *J* = 7.33, 1.77 Hz, 1 H), 8.73 (dd, *J* = 6.82, 1.77 Hz, 1 H), 8.29 (s, 1 H), 8.12 (d, *J* = 8.59 Hz, 1 H), 8.00 (d, *J* = 8.34 Hz, 1 H), 7.66 (t, *J* = 7.58 Hz, 1 H), 7.52–7.60 (m, 1 H), 6.89 (t, *J* = 7.07 Hz, 1 H), 3.66–3.77 (m, 2 H), 2.71 (t, *J* = 6.06 Hz, 2 H), 2.49 (s, 6 H). MS [*M* + 1] = 361.

12-Oxo-N-[2-(1-piperidyl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (8). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 1-(2-aminoethyl)piperidine (24.6 μ L, 0.17 mmol) according to method A to give 12-oxo-N-[2-(1-piperidyl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (25 mg, 0.062 mmol, 36.2 % yield) as an orange solid. ¹H NMR (400 MHz, CDCl₃) δ ppm 11.48 (br s, 1 H), 9.12 (s, 1 H), 8.96 (dd, *J* = 7.33, 1.77 Hz, 1 H), 8.74 (dd, *J* = 6.95, 1.64 Hz, 1 H), 8.44 (s, 1 H), 8.13 (d, *J* = 8.34 Hz, 1 H), 8.00 (d, *J* = 8.34 Hz, 1 H), 7.68 (dd, *J* = 8.08, 7.07 Hz, 1 H), 7.53–7.61 (m, 1 H), 6.90 (t, *J* = 7.07 Hz, 1 H), 3.75 (q, *J* = 5.81 Hz, 2 H), 2.73 (t, *J* = 6.19 Hz, 2 H), 2.61 (br s, 4 H),

1.78 (dt, $J = 11.24, 5.75$ Hz, 4 H), 1.54–1.59 (m, 2 H). MS [$M + 1$] = 401.

12-Oxo-*N*-(2-pyrrolidin-1-ylethyl)-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (9). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-pyrrolidin-1-ylethanamine (21.8 μ L, 0.17 mmol) according to method A to give 12-oxo-*N*-(2-pyrrolidin-1-ylethyl)-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (32.4 mg, 0.084 mmol, 48.7% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.65 (br s, 1 H), 9.11 (s, 1 H), 8.96 (dd, $J = 7.20, 1.64$ Hz, 1 H), 8.71–8.77 (m, 1 H), 8.37 (s, 1 H), 8.13 (d, $J = 8.34$ Hz, 1 H), 8.02 (d, $J = 7.83$ Hz, 1 H), 7.64–7.72 (m, 1 H), 7.54–7.63 (m, 1 H), 6.87–6.94 (m, 1 H), 3.79–3.88 (m, 2 H), 2.96–3.03 (m, 2 H), 2.89 (m, 2 H), 2.78 (m, 2 H), 2.00 (m, 4 H). MS [$M + 1$] = 387.

***N*-[2-(Diethylamino)ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (10).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N'*-diethylethane-1,2-diamine (24.3 μ L, 0.17 mmol) according to method A to give *N*-[2-(diethylamino)ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (18.2 mg, 0.047 mmol, 27% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.56–11.65 (m, 1 H), 9.12 (s, 1 H), 8.94–8.99 (m, 1 H), 8.75 (d, $J = 7.07$ Hz, 1 H), 8.41 (s, 1 H), 8.14 (d, $J = 8.08$ Hz, 1 H), 8.01 (d, $J = 7.83$ Hz, 1 H), 7.68 (t, $J = 7.58$ Hz, 1 H), 7.51–7.62 (m, 1 H), 6.91 (t, $J = 7.07$ Hz, 1 H), 3.77 (br s, 2 H), 2.83 (m, 6 H), 1.21 (t, $J = 7.20$ Hz, 6 H). MS [$M + 1$] = 389.

***N*-[2-(Dimethylamino)-1-methylethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (11).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N,N*,-dimethylpropane-1,2-diamine (22.2 μ L, 0.17 mmol) according to method A to give *N*-[2-(dimethylamino)-1-methyl-ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide hydrochloride (38.7 mg, 0.103 mmol, 60% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 9.12 (s, 1 H), 8.82 (td, $J = 6.63, 1.64$ Hz, 1 H), 8.31–8.35 (m, 1 H), 8.12 (d, $J = 8.59$ Hz, 1 H), 8.03 (d, $J = 8.08$ Hz, 1 H), 7.62–7.68 (m, 1 H), 7.53–7.58 (m, 1 H), 6.74–6.80 (m, 1 H), 3.47 (br s, 1 H), 2.91 (br s, 1 H), 2.43–2.49 (m, 1 H), 2.39 (s, 3 H), 2.20 (s, 3 H), 1.96 (br s, 3 H). MS [$M + 1$] = 375.

***N*-(Azetidin-3-yl)-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (12).** A solution of **30** (76 mg, 0.17 mmol) in chloroform (1 mL) was treated with trifluoroacetic acid (1.5 mL, 19.6 mmol) at room temperature for 24 h (for convenience). The solvents were removed in vacuo to give *N*-(azetidin-3-yl)-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide trifluoroacetate (76.1 mg, 0.17 mmol, 99% yield) as a yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 9.14–9.20 (m, 1 H), 9.10 (d, $J = 5.81$ Hz, 1 H), 8.67–8.74 (m, 1 H), 8.46 (s, 1 H), 8.20–8.27 (m, 1 H), 8.12 (s, 1 H), 7.92 (s, 1 H), 7.75 (d, $J = 7.83$ Hz, 1 H), 7.65 (d, $J = 6.82$ Hz, 1 H), 7.11 (t, $J = 7.20$ Hz, 1 H), 4.67 (dd, $J = 7.07, 4.55$ Hz, 1 H), 4.53 (d, $J = 7.33$ Hz, 2 H), 2.83 (br.s., 3 H). MS [$M + 1$] = 345.

***N*-[2-(Dimethylamino)propyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (13).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-(dimethylamino)propan-1-amine (21.1 mg, 0.21 mmol) according to method A to give *N*-[2-(dimethylamino)propyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (52 mg, 0.139 mmol, 80.6 % yield) as a yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.70 (br s, 1 H), 9.09 (s, 1 H), 8.94 (dd, $J = 7.33, 1.77$ Hz, 1 H), 8.73 (dd, $J = 6.82, 1.77$ Hz, 1 H), 8.27 (s, 1 H), 8.12 (d, $J = 8.59$ Hz, 1 H), 7.99 (d, $J = 8.59$ Hz, 1 H), 7.66 (dd, $J = 7.96, 6.95$ Hz, 1 H), 7.53–7.58 (m, 1 H), 6.89 (t, $J = 7.07$ Hz, 1 H), 3.77 (dt, $J = 14.02, 5.62$ Hz, 1 H), 3.40–3.48 (m, 1 H), 2.95–3.05 (m, 1 H), 2.51 (s, 6 H), 1.15 (d, $J = 6.32$ Hz, 3 H). MS [$M + 1$] = 375.

***N*-[4-(Dimethylamino)butyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (14).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N'*-dimethylbutane-1,4-diamine (24.5 μ L, 0.17 mmol) according to method A to give *N*-[4-(dimethylamino)butyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (22.1 mg, 0.057 mmol, 33% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.35–11.41 (m, 1 H), 9.13 (s, 1 H), 8.98 (dd, $J = 7.20, 1.64$ Hz, 1 H), 8.76 (dd, $J =$

6.95, 1.64 Hz, 1 H), 8.26 (s, 1 H), 8.14 (d, $J = 8.59$ Hz, 1 H), 8.06 (d, $J = 8.59$ Hz, 1 H), 7.66–7.72 (m, 1 H), 7.54–7.63 (m, 1 H), 6.92 (t, $J = 7.07$ Hz, 1 H), 3.62–3.73 (m, 2 H), 2.46–2.52 (m, 2 H), 2.32 (s, 6 H), 1.59–1.91 (m, 4 H). MS [$M + 1$] = 389.

***N*-[2-(Dimethylamino)ethyl]-11-oxopyrido[2,1-*b*]quinazoline-6-carboxamide (15).** This compound was synthesized from **6b** (40 mg, 0.17 mmol) and *N,N*-dimethylethylenediamine (14.7 mg, 0.17 mmol) according to method A to give *N*-[2-(dimethylamino)ethyl]-11-oxopyrido[2,1-*b*]quinazoline-6-carboxamide (19.8 mg, 0.064 mmol, 38% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, MeOD) δ ppm 9.32 (d, $J = 7.33$ Hz, 1 H), 8.91 (d, $J = 7.58$ Hz, 1 H), 8.51 (d, $J = 7.58$ Hz, 1 H), 8.07 (d, $J = 7.07$ Hz, 1 H), 7.99–8.03 (m, 2 H), 7.71 (t, $J = 7.45$ Hz, 1 H), 3.98 (t, $J = 5.81$ Hz, 2 H), 3.53 (t, $J = 5.81$ Hz, 2 H), 3.06 (s, 6 H). MS [$M + 1$] = 311.

***N*-[2-(Diethylamino)ethyl]-11-oxopyrido[2,1-*b*]quinazoline-6-carboxamide (16).** This compound was synthesized from **6b** (40 mg, 0.17 mmol) and *N,N'*-diethylethane-1,2-diamine (19.4 mg, 0.17 mmol) according to method A to give *N*-[2-(diethylamino)ethyl]-11-oxopyrido[2,1-*b*]quinazoline-6-carboxamide (25.2 mg, 0.075 mmol, 44.7% yield) as a yellow solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.44 (br s, 1 H), 9.06 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.83 (dd, $J = 6.82, 1.77$ Hz, 1 H), 8.45–8.51 (m, 1 H), 7.87–7.94 (m, 2 H), 7.54 (ddd, $J = 8.08, 5.68, 2.40$ Hz, 1 H), 7.04 (t, $J = 7.07$ Hz, 1 H), 3.71 (q, $J = 5.81$ Hz, 2 H), 2.69–2.84 (m, 6 H), 1.13 (t, $J = 7.20$ Hz, 6 H). MS [$M + 1$] = 339.

2-(Dimethylamino)ethyl 12-Oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxylate (17). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-dimethylaminoethanol (41.6 μ L, 0.41 mmol) according to method A to give 2-(dimethylamino)ethyl 12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxylate (47 mg, 0.13 mmol, 47.2 % yield) as an orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 9.10 (s, 1 H), 8.87 (dd, $J = 7.45, 1.64$ Hz, 1 H), 8.36 (s, 1 H), 8.11 (d, $J = 8.34$ Hz, 1 H), 8.02 (d, $J = 8.34$ Hz, 1 H), 7.78 (dd, $J = 6.69, 1.64$ Hz, 1 H), 7.64 (ddd, $J = 8.27, 6.76, 1.14$ Hz, 1 H), 7.52–7.57 (m, 1 H), 6.72 (dd, $J = 7.33, 6.57$ Hz, 1 H), 4.58 (t, $J = 5.81$ Hz, 2 H), 2.80 (t, $J = 5.68$ Hz, 2 H), 2.38 (s, 6 H). MS [$M + 1$] = 362.

***N*-[2-(Dimethylamino)ethyl]-*N*-methyl-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (18).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N,N'*-trimethylethylenediamine (21.3 μ L, 0.17 mmol) according to method A to give *N*-[2-(dimethylamino)ethyl]-*N*-methyl-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide trifluoroacetate (18.8 mg, 0.050 mmol, 29.1% yield) as an orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 9.14 (s, 1 H), 8.93 (d, $J = 7.33$ Hz, 1 H), 8.28 (s, 1 H), 8.14 (d, $J = 8.34$ Hz, 1 H), 8.04 (d, $J = 8.84$ Hz, 1 H), 7.93 (d, $J = 6.82$ Hz, 1 H), 7.67–7.74 (m, 1 H), 7.58–7.64 (m, 1 H), 6.97 (t, $J = 7.07$ Hz, 1 H), 4.12 (t, $J = 5.94$ Hz, 2 H), 3.57 (t, $J = 6.19$ Hz, 2 H), 3.12 (s, 6 H), 3.10 (s, 3 H). MS [$M + 1$] = 375.

***N*-[2-(Dimethylamino)ethyl]-*N*-ethyl-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (19).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N*-dimethyl-*N'*-ethylethylenediamine (27.1 μ L, 0.17 mmol) according to method A to give *N*-[2-(dimethylamino)ethyl]-*N*-ethyl-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide trifluoroacetate (36.1 mg, 0.093 mmol, 54% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 9.13 (s, 1 H), 8.87 (d, $J = 7.33$ Hz, 1 H), 8.21 (s, 1 H), 8.13 (d, $J = 8.34$ Hz, 1 H), 8.03 (d, $J = 8.59$ Hz, 1 H), 7.65–7.71 (m, 1 H), 7.56–7.62 (m, 2 H), 6.84 (t, $J = 7.07$ Hz, 1 H), 4.06 (m, 2 H), 3.62 (t, $J = 6.69$ Hz, 2 H), 3.39 (q, $J = 7.24$ Hz, 2 H), 3.12 (s, 6 H), 1.20 (t, $J = 7.07$ Hz, 3 H). MS [$M + 1$] = 389.

***N*-(2-Imidazol-1-ylethyl)-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (20).** This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-imidazol-1-ylethanamine (16.6 μ L, 0.17 mmol) according to method A to give *N*-(2-imidazol-1-ylethyl)-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (28.5 mg, 0.074 mmol, 43% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.57 (br s, 1 H), 9.08 (s, 1 H), 8.98 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.73 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.10 (t, $J = 8.34$ Hz, 3 H), 7.94 (s, 1 H), 7.66–7.72 (m, 3 H), 7.55–7.60 (m, 2 H),

7.22 (s, 1 H), 7.16 (s, 1 H), 6.91 (t, $J = 7.07$ Hz, 2 H), 4.32–4.37 (m, 2 H), 4.01–4.07 (m, 2 H). MS [$M + 1$] = 384.

12-Oxo-N-[2-(3-pyridyl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (21). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 3-(2-aminoethyl)pyridine (20.5 μ L, 0.17 mmol) according to method A to give 12-oxo-N-[2-(3-pyridyl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (55 mg, 0.14 mmol, 81% yield) as an orange solid. $^1\text{H NMR}$ (400 MHz, DMSO- d_6) δ ppm 11.39 (br s, 1 H), 9.12 (s, 1 H), 8.96 (dd, $J = 7.33, 1.77$ Hz, 1 H), 8.75 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.26 (s, 1 H), 8.13 (d, $J = 8.59$ Hz, 1 H), 8.03 (d, $J = 8.59$ Hz, 1 H), 7.64–7.72 (m, 1 H), 7.53–7.61 (m, 1 H), 6.91 (t, $J = 7.07$ Hz, 1 H), 3.64–3.74 (m, 2 H), 2.50–2.58 (m, 2 H). MS [$M + 1$] = 395.

12-Oxo-N-[2-(2-pyridyl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (22). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-(2-aminoethyl)pyridine (20.6 μ L, 0.17 mmol) according to method A to give 12-oxo-N-[2-(2-pyridyl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (40.7 mg, 0.103 mmol, 60% yield) as an orange solid. $^1\text{H NMR}$ (400 MHz, DMSO- d_6) δ ppm 11.39 (br s, 1 H), 9.12 (s, 1 H), 8.96 (dd, $J = 7.33, 1.77$ Hz, 1 H), 8.75 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.26 (s, 1 H), 8.13 (d, $J = 8.59$ Hz, 1 H), 8.03 (d, $J = 8.59$ Hz, 1 H), 7.64–7.72 (m, 1 H), 7.53–7.61 (m, 1 H), 6.91 (t, $J = 7.07$ Hz, 1 H), 3.64–3.74 (m, 2 H), 2.50–2.58 (m, 2 H). MS [$M + 1$] = 395.

12-Oxo-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (23). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 1-(2-aminoethyl)imidazolidin-2-one (19.6 μ L, 0.17 mmol) according to method A to give 12-oxo-N-[2-(2-oxoimidazolidin-1-yl)ethyl]-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (6.5 mg, 0.016 mmol, 9.4% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.54 (br s, 1 H), 9.12 (s, 1 H), 8.98 (dd, $J = 7.20, 1.64$ Hz, 1 H), 8.74 (d, $J = 7.07$ Hz, 1 H), 8.43 (s, 1 H), 8.12 (dd, $J = 12.63, 8.08$ Hz, 2 H), 7.66–7.71 (m, 1 H), 7.57 (dd, $J = 15.79, 8.72$ Hz, 2 H), 7.02 (s, 1 H), 6.91 (t, $J = 7.33$ Hz, 1 H), 3.80–3.88 (m, 2 H), 3.61–3.69 (m, 4 H), 3.47 (m, 2 H). MS [$M + 1$] = 402.

N-[2-(1H-Indol-3-yl)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (24). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and tryptamine (27.6 mg, 0.17 mmol) according to method A to give N-[2-(1H-indol-3-yl)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (22.9 mg, 0.053 mmol, 30.7% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.43–11.50 (m, 1 H), 9.04 (s, 1 H), 8.91–8.95 (m, 1 H), 8.77 (dd, $J = 6.82, 1.77$ Hz, 1 H), 8.06 (s, 2 H), 7.83 (d, $J = 7.33$ Hz, 1 H), 7.74 (d, $J = 8.08$ Hz, 1 H), 7.60–7.67 (m, 1 H), 7.54 (s, 1 H), 7.47 (s, 1 H), 7.34 (s, 2 H), 7.19–7.26 (m, 3 H), 7.16 (d, $J = 2.02$ Hz, 2 H), 6.90 (t, $J = 7.20$ Hz, 1 H), 4.08 (d, $J = 6.06$ Hz, 2 H), 3.27 (m, 2 H). MS [$M + 1$] = 433.

N-(2-Methylsulfonyl)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (25). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-methylsulfonyl ethanamine (21.2 mg, 0.17 mmol) according to method A to give N-(2-methylsulfonyl)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (2.1 mg, 0.0053 mmol, 3.1% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.93 (br s, 1 H), 9.12 (s, 1 H), 9.00 (dd, $J = 7.45, 1.64$ Hz, 1 H), 8.73 (dd, $J = 6.95, 1.64$ Hz, 1 H), 8.49 (s, 1 H), 8.12 (t, $J = 8.84$ Hz, 2 H), 7.67–7.72 (m, 1 H), 7.56–7.62 (m, 1 H), 6.92 (t, $J = 7.07$ Hz, 1 H), 4.16–4.22 (m, 2 H), 3.49–3.54 (m, 2 H), 3.07 (s, 3 H). MS [$M + 1$] = 396.

N-[3-(Dimethylamino)propyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (26). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N*-dimethyl-1,3-propanediamine (21.7 μ L, 0.17 mmol) according to method A to give N-[3-(dimethylamino)propyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (18.1 mg, 0.048 mmol, 28.1% yield) as an orange solid. $^1\text{H NMR}$ (400 MHz, DMSO- d_6) δ ppm 11.39 (br s, 1 H), 9.12 (s, 1 H), 8.96 (dd, $J = 7.33, 1.77$ Hz, 1 H), 8.75 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.26 (s, 1 H), 8.13 (d, $J = 8.59$ Hz, 1 H), 8.03 (d, $J = 8.59$ Hz, 1 H), 7.64–7.72 (m, 1 H), 7.53–7.61 (m, 1 H), 6.91 (t, $J =$

7.07 Hz, 1 H), 3.64–3.74 (m, 2 H), 2.50–2.58 (m, 2 H), 2.33 (s, 6 H), 1.98 (quin, $J = 7.14$ Hz, 2 H). MS [$M + 1$] = 375.

N-[2-(1-Methylpyrrolidin-2-yl)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (27). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 2-(2-aminoethyl)-1-methylpyrrolidine (22 mg, 25 μ L, 0.17 mmol) according to method A to give N-[2-(1-methylpyrrolidin-2-yl)ethyl]-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (18 mg, 0.045 mmol, 26% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.59 (br s, 1 H), 9.10 (s, 1 H), 8.98 (dd, $J = 7.33, 1.77$ Hz, 1 H), 8.70 (dd, $J = 6.82, 1.77$ Hz, 1 H), 8.28 (s, 1 H), 8.11 (t, $J = 7.71$ Hz, 2 H), 7.70 (dd, $J = 8.59, 7.33$ Hz, 1 H), 7.56–7.62 (m, 1 H), 6.92 (t, $J = 7.20$ Hz, 1 H), 3.66–3.88 (m, 1 H), 3.26 (m, 2 H), 3.16 (m, 1 H), 2.94 (br.s., 3 H), 2.86–2.92 (m, 1 H), 2.83 (d, $J = 4.04$ Hz, 1 H), 2.46–2.60 (m, 2 H), 2.20–2.36 (m, 2 H), 2.05–2.20 (m, 2 H). MS [$M + 1$] = 401.

N-[3-(Dimethylamino)propyl]-N-methyl-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (28). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N,N'*-trimethyl-1,3-propanediamine (25.3 μ L, 0.17 mmol) according to method A to give N-[3-(dimethylamino)propyl]-N-methyl-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide hydrochloride (27.7 mg, 0.071 mmol, 41.4% yield) as a yellow solid. $^1\text{H NMR}$ (400 MHz, DMSO- d_6) δ ppm 9.12 (s, 1 H), 8.77 (d, $J = 7.33$ Hz, 1 H), 8.32 (d, $J = 6.32$ Hz, 2 H), 8.10–8.21 (m, 1 H), 7.54–7.75 (m, 3 H), 6.90–7.01 (m, 1 H), 3.41 (m, 2 H), 3.10 (m, 3 H), 2.87–2.93 (m, 8 H), 2.13 (m, 2 H). MS [$M + 1$] = 389.

N-(1-Methyl-4-piperidyl)-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (29). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 4-amino-1-methylpiperidine (21.6 μ L, 0.17 mmol) according to method A to give N-(1-methyl-4-piperidyl)-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (32.4 mg, 0.084 mmol, 48.7% yield) as an orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.55 (d, $J = 8.34$ Hz, 2 H), 9.12 (s, 1 H), 8.97 (dd, $J = 7.33, 1.77$ Hz, 1 H), 8.75 (dd, $J = 6.82, 1.77$ Hz, 1 H), 8.22 (s, 1 H), 8.13 (d, $J = 8.84$ Hz, 1 H), 8.03 (d, $J = 8.59$ Hz, 1 H), 7.68–7.72 (m, 1 H), 7.56–7.61 (m, 1 H), 6.92 (t, $J = 7.07$ Hz, 1 H), 4.19 (br s, 1 H), 2.96 (br s, 2 H), 2.43 (s, 3 H), 2.33 (br s, 2 H), 2.21 (d, $J = 9.60$ Hz, 2 H), 1.85–1.95 (m, 2 H). MS [$M + 1$] = 387.

tert-Butyl 3-[(12-Oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carbonyl)amino]azetidine-1-carboxylate (30). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 1-Boc-3-(amino)azetidine (29.7 mg, 0.17 mmol) according to method A to give *tert*-butyl 3-[(12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carbonyl)amino]azetidine-1-carboxylate (76 mg, 0.17 mmol, 99% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 11.98 (br s, 1 H), 9.15 (s, 1 H), 9.00 (dd, $J = 7.33, 1.77$ Hz, 1H), 8.73 (dd, $J = 7.07, 1.77$ Hz, 1 H), 8.25 (s, 1 H), 8.13 (dd, $J = 15.56, 7.71$ Hz, 2 H), 7.70–7.76 (m, 1 H), 7.58–7.64 (m, 1 H), 6.91–6.95 (m, 1 H), 4.90 (d, $J = 6.32$ Hz, 1 H), 4.46–4.53 (m, 2 H), 4.11 (br s, 2 H), 1.52 (s, 9 H). MS [$M + 1$] = 445.

4-(4-Isopropylpiperazine-1-carbonyl)-12H-benzo[g]pyrido[2,1-b]quinazoline-12-one (31). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and 1-isopropylpiperazine (26.4 μ L, 0.17 mmol) according to method A to give 4-(4-isopropylpiperazine-1-carbonyl)-12H-benzo[g]pyrido[2,1-b]quinazoline-12-one (40.9 mg, 0.102 mmol, 59.4% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz, CDCl_3) δ ppm 9.11–9.14 (m, 1 H), 8.79–8.82 (m, 1 H), 8.30 (s, 1 H), 8.10–8.15 (m, 1 H), 7.99–8.03 (m, 1 H), 7.62–7.68 (m, 1 H), 7.53–7.59 (m, 1 H), 7.45 (dd, $J = 6.57, 1.52$ Hz, 1 H), 6.73–6.79 (m, 1 H), 4.10 (m, 2 H), 3.87 (m, 2 H), 3.48 (m, 1 H), 3.36 (m, 1 H), 2.74–2.92 (m, 1 H), 2.68 (m, 1 H), 2.40 (m, 1 H), 1.10 (d, $J = 6.57$ Hz, 6 H). MS [$M + 1$] = 401.

N-Methyl-N-(1-methylpyrrolidin-3-yl)-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide (32). This compound was synthesized from **6a** (50 mg, 0.17 mmol) and *N,N'*-dimethyl-3-aminopyrrolidine (19.7 mg, 0.17 mmol) according to method A to give N-methyl-N-(1-methylpyrrolidin-3-yl)-12-oxo-12H-benzo[g]pyrido[2,1-b]quinazoline-4-carboxamide trifluoroacetate (6 mg, 0.016 mmol, 9.0% yield) as a yellow-orange solid. $^1\text{H NMR}$ (400 MHz,

MeOD) δ ppm 9.11 (s, 1 H), 8.83–8.92 (m, 1 H), 8.24–8.33 (m, 1 H), 8.19 (d, J = 8.08 Hz, 1 H), 8.07 (d, J = 8.34 Hz, 1 H), 7.92 (s, 1 H), 7.55–7.74 (m, 3 H), 6.95 (q, J = 7.33 Hz, 1 H), 4.60 (d, J = 9.35 Hz, 1 H), 4.25 (d, J = 11.87 Hz, 1 H), 4.02–4.14 (m, 1 H), 3.47–3.62 (m, 1 H), 3.17–3.28 (m, 4 H), 3.07 (m, 3 H), 2.67–2.85 (m, 2 H). MS [$M + 1$] = 387.

4-[(3*S*)-3-(Dimethylamino)pyrrolidine-1-carbonyl]-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-12-one (33). This compound was synthesized from 6a (50 mg, 0.17 mmol) and (3*S*)-(-)-3-(dimethylamino)pyrrolidine (19.7 mg, 0.17 mmol) according to method A to give 4-[(3*S*)-3-(dimethylamino)pyrrolidine-1-carbonyl]-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-12-one hydrochloride (34.1 mg, 0.088 mmol, 51.2% yield) as a yellow-orange solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 1.96 (br s, 2 H), 9.12 (s, 1 H), 8.82 (td, J = 6.63, 1.64 Hz, 1 H), 8.31–8.35 (m, 1 H), 8.12 (d, J = 8.59 Hz, 1 H), 8.03 (d, J = 8.08 Hz, 1 H), 7.62–7.68 (m, 1 H), 7.53–7.58 (m, 1 H), 6.74–6.80 (m, 1 H), 3.47 (m, 2 H), 2.91 (m, 2 H), 2.43–2.49 (m, 1 H), 2.39 (s, 3 H), 2.24–2.33 (m, 1 H), 2.20 (s, 3 H), 2.11 (m, 1 H). MS [$M + 1$] = 387.

4-[3-(Diethylamino)pyrrolidine-1-carbonyl]-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-12-one (34). This compound was synthesized from 6a (50 mg, 0.17 mmol) and 3-(diethylamino)pyrrolidine (24.5 mg, 0.17 mmol) according to method A to give 4-[3-(diethylamino)pyrrolidine-1-carbonyl]-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-12-one (54.7 mg, 0.13 mmol, 76.6% yield) as a yellow-orange solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 9.12 (s, 1 H), 8.82 (dd, J = 7.58, 1.52 Hz, 1 H), 8.28–8.37 (m, 2 H), 8.12 (d, J = 8.59 Hz, 1 H), 7.65–7.74 (m, 2 H), 7.57–7.63 (m, 1 H), 6.97–7.02 (m, 1 H), 4.10 (m, 1 H), 3.97 (m, 1 H), 3.81–3.93 (m, 1 H), 3.63 (m, 1 H), 3.38 (d, J = 7.33 Hz, 1 H), 3.14 (m, 1 H), 2.87 (m, 1 H), 2.33 (br s, 1 H), 2.26 (br s, 1 H), 1.33–1.38 (m, 1 H), 1.26–1.33 (m, 1 H), 1.14 (t, J = 7.07 Hz, 3 H), 1.01 (t, J = 7.07 Hz, 3 H). MS [$M + 1$] = 415.

N-[2-(Diisopropylamino)ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (35). This compound was synthesized from 6a (50 mg, 0.17 mmol) and *N,N*-diisopropylethylenediamine (29.9 μL , 0.17 mmol) according to method A to give *N*-[2-(diisopropylamino)ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (33 mg, 0.079 mmol, 46 % yield) as an orange solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 11.07 (br s, 1 H), 9.11 (s, 1 H), 8.92 (d, J = 7.33 Hz, 1 H), 8.58 (d, J = 6.32 Hz, 1 H), 8.42 (s, 1 H), 8.31 (d, J = 7.83 Hz, 1 H), 8.09 (d, J = 7.83 Hz, 1 H), 7.73 (t, J = 7.07 Hz, 1 H), 7.57–7.66 (m, 1 H), 7.05 (t, J = 7.33 Hz, 1 H), 3.50 (d, J = 5.56 Hz, 2 H), 3.13–3.23 (m, 2 H), 2.66–2.75 (m, 2 H), 1.07 (d, J = 6.57 Hz, 12 H). ^1H NMR (400 MHz, CDCl_3) δ ppm 11.33 (br s, 1 H), 9.12 (s, 1 H), 8.96 (d, J = 6.06 Hz, 1 H), 8.76 (d, J = 6.57 Hz, 1 H), 8.36 (s, 1 H), 8.13 (d, J = 8.08 Hz, 1 H), 8.01 (d, J = 9.09 Hz, 1 H), 7.63–7.72 (m, 1 H), 7.52–7.61 (m, 1 H), 6.90 (t, J = 7.07 Hz, 1 H), 3.66 (d, J = 5.56 Hz, 2 H), 3.22 (d, J = 6.57 Hz, 2 H), 2.81 (br s, 2 H), 1.14 (d, J = 6.32 Hz, 12 H). MS [$M + 1$] = 417.

N-[2-(Morpholinoethyl)-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (36). This compound was synthesized from 6a (50 mg, 0.17 mmol) and *N*-(2-aminoethyl)morpholine (22.6 μL , 0.17 mmol) according to method A to give *N*-(2-morpholinoethyl)-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (28.7 mg, 0.071 mmol, 41.4 % yield) as an orange solid. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ ppm 11.50 (br s, 1 H), 9.12 (s, 1 H), 8.96 (dd, J = 7.33, 1.77 Hz, 1 H), 8.75 (dd, J = 6.82, 1.77 Hz, 1 H), 8.38 (s, 1 H), 8.13 (d, J = 8.59 Hz, 1 H), 8.00 (d, J = 8.34 Hz, 1 H), 7.64–7.73 (m, 1 H), 7.54–7.62 (m, 1 H), 6.90 (t, J = 7.07 Hz, 1 H), 3.88–3.97 (m, 4 H), 3.77 (q, J = 5.89 Hz, 2 H), 2.78 (t, J = 6.19 Hz, 2 H), 2.68 (br s, 4 H). MS [$M + 1$] = 403.

N-[2-(4-Methylpiperazin-1-yl)ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (37). This compound was synthesized from 6a (50 mg, 0.17 mmol) and 2-(4-methylpiperazin-1-yl)ethanamine (27.6 μL , 0.17 mmol) according to method A to give *N*-[2-(4-methylpiperazin-1-yl)ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (11.7 mg, 0.028 mmol, 16.3% yield) as a yellow-orange solid. ^1H NMR (400 MHz, CDCl_3) δ ppm 11.46 (br s, 1 H), 9.14 (s, 1 H), 8.98 (dd, J = 7.33, 1.77 Hz, 1 H), 8.76 (dd, J = 6.82, 1.77 Hz, 1 H), 8.43 (s, 1 H), 8.16 (d, J = 8.59 Hz, 1 H), 8.08 (d, J = 8.34 Hz, 1 H), 7.65–7.73 (m, 1 H), 7.60 (dd, J = 6.82, 1.26 Hz, 1

H), 6.92 (t, J = 7.07 Hz, 1 H), 3.74–3.83 (m, 2 H), 2.60–2.88 (m, 10 H), 2.38 (s, 3 H). MS [$M + 1$] = 416.

N-[2-[2-Methoxyethyl(methyl)amino]ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide (38). This compound was synthesized from 6a (50 mg, 0.17 mmol) and *N'*-(2-methoxyethyl)-*N'*-methylethane-1,2-diamine (27.3 mg, 0.21 mmol) according to method A to give *N*-[2-[2-methoxyethyl(methyl)amino]ethyl]-12-oxo-12*H*-benzo[*g*]pyrido[2,1-*b*]quinazoline-4-carboxamide trifluoroacetate (15 mg, 0.037 mmol, 21.5 % yield) as an orange gum. ^1H NMR (400 MHz, CDCl_3) δ ppm 11.79 (br s, 1 H), 9.10 (s, 2 H), 9.00 (dd, J = 7.33, 1.52 Hz, 1 H), 8.68–8.73 (m, 1 H), 8.43 (s, 1 H), 8.10 (dd, J = 13.64, 8.34 Hz, 3 H), 7.70 (t, J = 7.58 Hz, 2 H), 7.56–7.62 (m, 2 H), 6.94 (t, J = 7.20 Hz, 1 H), 4.07 (br s, 2 H), 3.80 (t, J = 4.55 Hz, 2 H), 3.68 (br s, 1 H), 3.55 (br s, 2 H), 3.36–3.41 (m, 4 H), 3.07 (s, 3 H). ^{19}F NMR (376 MHz, CDCl_3) δ ppm –170.87 (br s, 3 F). MS [$M + 1$] = 405.

Metabolic Stability. Test compounds (1 μM) were incubated in duplicate 100 μL incubations for each time point (0, 5, 20, 30, and 60 min) in a 37 $^\circ\text{C}$ water bath. Reaction mixes contained 0.5 mg/mL pooled mixed gender human liver microsomes (Xenotech, LLC) in incubation buffer (10 mM MgCl_2 , 0.1 M potassium phosphate, pH 7.4). After a 5 min preincubation, reactions were initiated with addition of β -NADPH, nicotinamide adenine dinucleotide phosphate (final concentration 1 mM). Reactions were terminated by addition of 200 μL of 0.1% formic acid in acetonitrile (ACN) with internal standard (400 ng/mL warfarin). Reactions were vortexed then centrifuged for 15 min at 4000 rpm. Supernatants were transferred and diluted with equal volume of 0.1% formic acid in water. The half-life and the intrinsic clearance were determined using Michaelis–Menten nonlinear regression analysis as shown in the following equations: $T_{1/2}(\text{min}) = \ln(2)/k$ and $\text{Cl}_{\text{int}} ((\mu\text{L}/\text{min})/\text{mg protein}) = 1000k/[\text{HLM}]$ (mg/mL), where k is the rate constant equal to the absolute value of the slope of the compound disappearance in the plot of the natural log of percent remaining vs time.

The samples were quantified using an Agilent 6540 QTOF with jet stream electrospray ionization source (ESI) and Agilent 1290 UHPLC front-end. Chromatographic separation was achieved over 1 min using a 2.1 mm \times 50 mm, 1.8 μm , Zorbax Eclipse Plus RRHD column (Agilent Technologies) with a binary gradient starting at 0.1% formic acid in 5% ACN in water. The ACN concentration increased to 95% between 0.2 and 0.4 min and held until 0.7 min. The gradient returned to initial conditions at 0.75 min. The ESI source conditions were as follows: drying gas temp, 350 $^\circ\text{C}$; sheath gas temp, 400 $^\circ\text{C}$; drying and sheath gas flow, 12 L/min; nebulizer, 60 psig; voltage of cap, 3000 V; nozzle, 600 V; fragmentor, 150 V; skimmer, 100 V; OCT 1 RF Vpp, 750 V. The acquisition was performed by full scan MS from m/z 100 to m/z 500.

Cells and Viability Assay. The cells were maintained at 37 $^\circ\text{C}$ in a humidified atmosphere containing 5% CO_2 . U2OS osteosarcoma cells were cultured in DMEM supplemented with 15% fetal bovine serum. Cells were plated in 96-well plates at a density of 10 000 cells/well in triplicate and incubated for 48 h with the compounds. Viability was determined using WST-1 cell proliferation reagent (Roche Diagnostics).

Immunofluorescence and Epifluorescence Microscopy. U2OS cells grown on coverslips were fixed in 3.5% paraformaldehyde, permeabilized with 0.5% NP-40, and blocked with 3% BSA as described in ref 13. Cells were stained for RPA194 (C-1, Santa Cruz Biotechnology) and NCL (4E2, Abcam). Alexa 488 and Alexa 594 conjugated anti-mouse or anti-rabbit antibodies were from Invitrogen. DNA was counterstained with DAPI (Invitrogen). Images were captured using Axioplan2 fluorescence microscope (Zeiss) equipped with AxioCam HRc CCD camera and AxioVision 4.5 software using EC Plan-Neofluar 20 \times /0.75 objective (Zeiss).

Determination of RPA194 and NCL IC₅₀. U2OS cells grown on coverslips were treated with the compounds at 0.1, 0.5, 1, 5, and 10 μM or treated with vehicle (DMSO) for 3 h and fixed and stained as above. All compounds, except when indicated, were tested in duplicate independent biological experiments. Immunostaining for NCL and RPA194 was conducted separately, and cells were counterstained for

DNA. Two to four fields of each treatment were captured using epifluorescence microscopy as above and contained an average of 200 cells/analysis. The images were quantified using FrIDA image analysis software as described in ref 14. Hue saturation and brightness range were defined individually for RPA194 and NCL, and all values were normalized to the DNA content. The fold change to control was determined. IC₅₀ was determined by GraphPad Prism for Windows (version 6.01) using a three-parameter fit.

Immunoblotting. Lysis of cells was conducted in 0.5% NP-40 buffer (25 mM Tris-HCl, pH 8.0, 120 mM NaCl, 0.5% NP-40, 4 mM NaF, 100 μ M Na₂VO₄, 100 KIU/mL aprotinin, 10 μ g/mL leupeptin). Proteins were separated on SDS-PAGE gel and blotted as in ref 14. The following antibodies were used: NCL (4E2, Abcam), RPA194 (C-1, Santa Cruz Biotechnology), GAPDH (Europa Bioproducts). HRP-conjugated secondary antibodies were from DAKO.

AUTHOR INFORMATION

Corresponding Author

*Phone: +1-410-502-9748. Fax: +1-410-502-2821. E-mail: mlaiho1@jhmi.edu.

Present Address

#L.C.: Department of Chemistry, Yale University, New Haven, CT 06520, U.S.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This work has been supported by NIH Grants P30 CA006973 and 1R01CA172069 (M.L.) and Johns Hopkins University start-up funds.

ABBREVIATIONS USED

NCL, nucleolin; Pol I, RNA polymerase I; r, ribosomal

REFERENCES

- (1) Hernandez-Verdun, D. Nucleolus: from structure to dynamics. *Histochem. Cell. Biol.* **2006**, *125*, 127–137.
- (2) Haag, J. R.; Pikaard, C. S. RNA polymerase I: a multifunctional molecular machine. *Cell* **2007**, *131*, 1224–1225.
- (3) Russell, J.; Zomerdijk, J. C. The RNA polymerase I transcription machinery. *Biochem. Soc. Symp.* **2006**, *73*, 203–216.
- (4) Comai, L. Mechanism of RNA polymerase I transcription. *Adv. Protein Chem.* **2004**, *67*, 123–155.
- (5) Boulon, S.; Westman, B. J.; Hutten, S.; Boisvert, F. M.; Lamond, A. I. The nucleolus under stress. *Mol. Cell* **2010**, *40*, 216–227.
- (6) Montanaro, L.; Treré, D.; Derenzini, M. Nucleolus, ribosomes, and cancer. *Am. J. Pathol.* **2008**, *173*, 301–310.
- (7) Grummt, I. Wisely chosen paths—regulation of rRNA synthesis. *FEBS J.* **2010**, *277*, 4626–4639.
- (8) Bywater, M. J.; Pearson, R. B.; McArthur, G. A.; Hannan, R. D. Dysregulation of the basal RNA polymerase transcription apparatus in cancer. *Nat. Rev. Cancer* **2013**, *13*, 299–314.
- (9) Whitesell, L.; Lindquist, S. Inhibiting the transcription factor HSF1 as an anticancer strategy. *Expert Opin. Ther. Targets* **2009**, *13*, 469–478.
- (10) Drygin, D.; Lin, A.; Bliesath, J.; Ho, C. B.; O'Brien, S. E.; Proffitt, C.; Omori, M.; Haddach, M.; Schwaebe, M. K.; Siddiqui-Jain, A.; Streiner, N.; Quin, J. E.; Sanij, E.; Bywater, M. J.; Hannan, R. D.; Ryckman, D.; Anderes, K.; Rice, W. G. Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. *Cancer Res.* **2011**, *71*, 1418–1430.
- (11) Haddach, M.; Schwaebe, M. K.; Michaux, J.; Nagasawa, J.; O'Brien, S. E.; Whitten, J. P.; Pierre, F.; Kerdoncuff, P.; Darjania, L.; Stansfield, R.; Drygin, D.; Anderes, K.; Proffitt, C.; Bliesath, J.; Siddiqui-Jain, A.; Omori, M.; Huser, N.; Rice, W. G.; Ryckman, D. M. Discovery of CX-5461, the first direct and selective inhibitor of RNA

polymerase I, for cancer therapeutics. *ACS Med. Chem. Lett.* **2012**, *3*, 602–606.

(12) Bywater, M. J.; Poortinga, G.; Sanij, E.; Hein, N.; Peck, A.; Cullinane, C.; Wall, M.; Cluse, L.; Drygin, D.; Anderes, K.; Huser, N.; Proffitt, C.; Bliesath, J.; Haddach, M.; Schwaebe, M. K.; Ryckman, D. M.; Rice, W. G.; Schmitt, C.; Lowe, S. W.; Johnstone, R. W.; Pearson, R. B.; McArthur, G. A.; Hannan, R. D. Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. *Cancer Cell* **2012**, *22*, 51–65.

(13) Peltonen, K.; Colis, L.; Liu, H.; Jäämaa, S.; Moore, H. M.; Enbäck, J.; Laakkonen, P.; Vaahtokari, A.; Jones, R. J.; af Hällström, T. M.; Laiho, M. Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. *PLoS One* **2010**, *5*, e12996.

(14) Peltonen, K.; Colis, L.; Liu, H.; Trivedi, R.; Moubarek, M. S.; Moore, H. M.; Bai, B.; Rudek, M. A.; Bieberich, C. J.; Laiho, M. A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. *Cancer Cell* **2014**, *25*, 77–90.

(15) Mukherjee, A.; Sasikala, W. D. Drug–DNA intercalation: from discovery to the molecular mechanism. *Adv. Protein Chem. Struct. Biol.* **2013**, *92*, 1–62.